Loading…
Employees: 371
Size REGENXBIO (RGNX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $503M, the 2693rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $7.62 on 6 Nov 2026.
Performance Over six months the shares fell 27.8%, against -18.1% for the median peer and -1.1% for the United States market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue grew 12.0% over the last twelve months (peer median +7.0%); the operating margin is -94.1% (peer median 10.0%).
Valuation It trades at 3.7× enterprise value to sales against a peer median of 4.0× (7th cheapest of 18).
Capital Return on invested capital runs 69.1 points below its cost of capital (9.2% WACC).
Short interest Short interest is 15.2% of the free float (15 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $174M | $170M | $83.3M | $90.2M | $113M |
| Revenue growth | — | +105% | -8% | -20% | — |
| Gross profit | $135M | $135M | $33.5M | $35.7M | $45.3M |
| EBITDA | -$149M | -$146M | -$215M | -$251M | -$250M |
| Net income | -$196M | -$194M | -$227M | -$263M | -$280M |
| Free cash flow | -$250M | -$126M | -$176M | -$228M | -$238M |
| Capital expenditure | $2.99M | $2.41M | $2.44M | $9.96M | $30.7M |
| Total debt | $250M | $261M | $142M | $89.3M | $94.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RGNX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.8% | -8.5% | 9th highest of 21 |
| 6-month return | -27.8% | -18.1% | 7th lowest of 20 |
| Distance from 52-week high | -52.9% | -41.9% | 4th lowest of 21 |
| Revenue growth (TTM) | +12.0% | +7.0% | 8th highest of 19 |
| Operating margin | -94.1% | 10.0% | 2nd lowest of 18 |
| EV / Sales | 3.7× | 4.0× | 7th cheapest of 18 |
| ROIC minus cost of capital | -69.1 pp | -2.1 pp | 3rd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| REGENXBIO RGNX | United States | $503M | -28% | +12% | -94% | 3.7× | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $502M | -49% | +3% | -39% | 3.3× | 47.1% | -12.3% |
| Gyre Therapeutics GYRE | United States | $505M | -36% | +17% | -11% | 4.1× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $510M | +64% | n/a | n/a | n/a | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $496M | -44% | +51% | 27% | 3.9× | 1.7% | +14.5% |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $495M | +18% | +10% | 15% | 5.2× | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $495M | -16% | +23% | -61% | 19.6× | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | 9.8× | n/a | n/a |
| Electra Therapeutics ETRA | United States | $490M | n/a | n/a | n/a | n/a | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $489M | -11% | -49% | 5% | 2.5× | -2.6% | -5.6% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | 4.0× | 6.7% | -4.1% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $520M | -20% | -1% | 10% | 2.1× | n/a | n/a |
| Daewoong 003090.KS | South Korea | $485M | -29% | +5% | 11% | 0.9× | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $484M | -23% | -14% | 12% | 0.5× | -18.6% | +6.3% |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | 3.9× | 10.2% | +9.1% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | 28.5× | n/a | n/a |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $483M | +9% | -4% | 3% | 1.4× | 13.4% | +1.4% |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 11.3× | 12.9% | +126.7% |
| Alpha Teknova TKNO | United States | $482M | +104% | +12% | -35% | 11.3× | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 73.5× | n/a | n/a |